Navigation Links
Celladon Corporation is a Finalist for the 2013 Red Herring Top 100 North America Award
Date:5/7/2013

start-ups' solid roots in corporate America, embracing their innovations. By all metrics, it emphasizes the United States' entrepreneurial excellence," said Alex Vieux , publisher and CEO of Red Herring.

Finalist selections for the 2013 edition of the Red Herring 100 North America award are based upon technological innovation, management strength, market size, investor record, customer acquisition and financial health. During the several months leading up to the announcement, hundreds of companies in the fields of security, Web 2.0, software, hardware, life sciences, cloud, mobile and others completed their submissions to qualify for the award.

The Top 100 winners will be announced at a special awards ceremony the evening of May 23 at the event.

About MYDICAR
MYDICAR is a genetically targeted enzyme replacement therapy intended to restore levels of SERCA2a, a regulator of calcium cycling in the heart and cardiac contractility. SERCA2a levels decline in all forms of late-stage HF resulting in deficient heart function. With MYDICAR, the SERCA2a gene is delivered using recombinant adeno-associated virus (AAV) as the vector. AAV is a naturally occurring virus not associated with any disease in humans. MYDICAR is delivered in a single dose directly to the heart during a routine outpatient cardiac catheterization procedure, similar to an angiogram. MYDICAR is synergistic and additive across current HF treatments such as ACE inhibitors, beta-blockers, sprinolactone/diuretics, and biventricular pacing devices. No treatment substitution decision is required by the treating physician. A recent Phase 2 clinical trial demonstrated sustained improvement at one year in cardiac function parameters and quality of life. A 200 patient Phase 2b study of MYDICAR was initiated in August, 2012

About Celladon
Celladon is a private
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celladon Corporation Receives Notice of Allowance from European Patent Office
2. Celladon Corporation Receives Patent from United States Patent and Trademark Office
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
5. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
6. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
7. Luminex Corporation Reports First Quarter 2012 Results
8. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
9. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
10. Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... (Nasdaq: SLTM ), a global leader in the ... the Tenth Annual JMP Securities Research Conference at the Ritz-Carlton ... pm Pacific Time. Stephen J. Fanning, Chairman, President and Chief ... corporate events. Attendance at this conference is by ...
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERT ) ... medical devices to biopharmaceutical and healthcare organizations and ... efficacy services in drug development, announced today results ...  Unless otherwise noted, all comparative numbers refer to ...
Cached Medicine Technology:Solta Medical to Present at the JMP Securities Research Conference 2ERT Reports First Quarter 2011 Operating Results 2ERT Reports First Quarter 2011 Operating Results 3ERT Reports First Quarter 2011 Operating Results 4ERT Reports First Quarter 2011 Operating Results 5ERT Reports First Quarter 2011 Operating Results 6ERT Reports First Quarter 2011 Operating Results 7ERT Reports First Quarter 2011 Operating Results 8ERT Reports First Quarter 2011 Operating Results 9ERT Reports First Quarter 2011 Operating Results 10ERT Reports First Quarter 2011 Operating Results 11
(Date:4/24/2014)... BrainHealth will bring together national experts to discuss ... its inaugural Brain Health Summit, titled "The Human ... include Dr. Sandra Bond Chapman, founder and chief ... Chuck Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) ... and Early Learning, U.S. Department of Education. The ...
(Date:4/24/2014)... the relevance of palliation in advanced cancer are ... trials (RCTs). This is the result of an ... Efficiency in Health Care (IQWiG), which has now ... external experts, IQWiG analysed studies on four solid ... and pancreatic cancer. For this purpose, the research ...
(Date:4/24/2014)... is better to give than to receive at least ... study suggests. , The study found that 15- and 16-year-olds ... money to family members, are less likely to become depressed ... or keeping the money for themselves. , The researchers detail ... of Sciences . , The study focused on the ventral ...
(Date:4/24/2014)... CORVALLIS, Ore. An Oregon State University researcher has ... severity of the symptoms of autism spectrum disorder in ... the be the first to show a direct relationship ... of fine and gross motor skills should be included ... Megan MacDonald, an assistant professor in OSU,s College of ...
(Date:4/24/2014)... a scientist at the University of York reveals that ... development of the nervous system may also play a ... A research team, led by Dr Will Brackenbury, a ... at York, has studied how voltage-gated sodium channels assist ... found in the membranes of excitable cells, such as ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2
... , , ... Corp., the leader in clinically proven brain fitness software, and ... collaboration to empower individuals with knowledge and tools that can ... this first-of-its-kind offer, consumers will have the opportunity to complement ...
... , , HOUSTON, Sept. ... that Dan Moore, President and Chief Executive Officer, and Greg Browne, ... Conference in New York on Tuesday, September 22, 2009 at 4:00 ... live and by replay at http://cc.talkpoint.com/ubsx001/092109a_ke/?entity=82_IT8KY1C . ...
... , PORTLAND, Maine, Sept. 10 ... Council for Disability Awareness (CDA) reveals a surge in the number ... , , The CDA,s 4(th) Annual Long-Term Disability ... identifies continuing and emerging disability trends among U.S. workers. Fifteen CDA ...
... STERIS Corporation (NYSE: STE ) today announced that the ... in New York on Tuesday, September 22, 2009. Michael J. ... p.m., Eastern time. , , The presentation can ... at www.steris-ir.com . The presentation will be ...
... ... Pioneer in the Development of Telehealth-Supported Solutions for Connected Care , ... Minneapolis, MN (PRWEB) September 10, 2009 ... Lenzmeier as chairman. Founded in 1993, ATI is the pioneer in the development and ...
... , , ANN ... biopharmaceutical company, today announced positive efficacy results from the second ... study for Ophena(TM) (ospemifene tablets), the company,s investigational ... (VVA). This study, together with the recent completion of ...
Cached Medicine News:Health News:Silicon Valley Firms Partner to Promote Brain and Body Awareness 2Health News:Silicon Valley Firms Partner to Promote Brain and Body Awareness 3Health News:Cyberonics to Present at UBS Global Life Sciences Conference 2Health News:Disability Rates Continue Steady Climb, According to CDA's 2008 Disability Claims Review 2Health News:Disability Rates Continue Steady Climb, According to CDA's 2008 Disability Claims Review 3Health News:STERIS To Present at the UBS Global Life Sciences Conference on September 22, 2009 2Health News:STERIS To Present at the UBS Global Life Sciences Conference on September 22, 2009 3Health News:Allen Lenzmeier Elected Chairman of the Board of Directors of American TeleCare, Inc. (ATI) 2Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 2Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 3Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: